Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1987-12-1
|
pubmed:abstractText |
From October 1983 to September 1985, 84 patients with superficial bladder tumor (Ta, Tl, Tis) were treated with sequential instillation of mitomycin C (MMC) and adriamycin (ADM). Doses of 20 mg MMC on day 1 and 40 mg ADM on day 2 were instilled into the bladder and retained for at least 2 h; this was repeated once a week for 5 consecutive weeks. Patients who achieved complete response (CR), were randomized and underwent prophylactic treatment taking the form of either intermittent instillation of MMC or daily oral administration of 5-fluorouracil. Of 79 evaluable patients, 72 (91%) had received prior treatment for superficial bladder tumors, 69 (87%) had high-grade tumors, and 18 (23%) had non-papillary Tis. The overall response rate was 68%, made up of CR in 43 patients (54%) and partial response (PR) in 11 (14%). Patients with either five or more tumors or tumors larger than 1 cm showed a significantly lower response rate than those with fewer than five tumors and tumors smaller than 1 cm, respectively. There was no correlation between tumor growth pattern, tumor grade and response rate, though non-papillary Tis appeared to respond better than papillary tumors. A history of prior instillation therapy or of toxicity to this treatment had no significant influence on the response rate. Although no systemic toxicity was observed, 62 patients (74%) experienced cystitis and the treatment had to be discontinued within 4 weeks in 13 of 33 cases with severe symptoms. The preliminary conclusion of prophylactic treatment was that intermittent instillation of MMC was superior to 5-FU medication in reducing the recurrence rate for at least 2 years after the treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0344-5704
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20 Suppl
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
S52-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3117399-Administration, Intravesical,
pubmed-meshheading:3117399-Adult,
pubmed-meshheading:3117399-Aged,
pubmed-meshheading:3117399-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3117399-Carcinoma,
pubmed-meshheading:3117399-Carcinoma, Papillary,
pubmed-meshheading:3117399-Doxorubicin,
pubmed-meshheading:3117399-Drug Administration Schedule,
pubmed-meshheading:3117399-Female,
pubmed-meshheading:3117399-Humans,
pubmed-meshheading:3117399-Male,
pubmed-meshheading:3117399-Middle Aged,
pubmed-meshheading:3117399-Mitomycin,
pubmed-meshheading:3117399-Mitomycins,
pubmed-meshheading:3117399-Urinary Bladder Neoplasms
|
pubmed:year |
1987
|
pubmed:articleTitle |
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.
|
pubmed:affiliation |
Department of Urology, Tokyo Medical and Dental University Hospital, Japan.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|